Advanced Enzyme Q2 FY27 Revenue Up 16% to ₹214.5 Crore, PAT Rises 14%
Advanced Enzyme Technologies reported Q2 FY27 consolidated revenue of ₹214.5 crore, up 16% YoY. PAT increased 14% to ₹51.2 crore. Revenue grew 12% QoQ. Animal Nutrition and Bio-Processing segments showed strong growth of 37% and 43% respectively. The company launched its nutraceutical brand, Wellfa, in India.
The announcement includes strong financial results with significant growth in revenue and profit, alongside strategic initiatives like new product launches and market expansion, which are material to the company's performance and investor outlook.
The company has reported positive year-on-year and quarter-on-quarter growth in revenue and profits, with strong performance in key operational segments and a positive outlook for future growth initiatives.
Advanced Enzyme Technologies Limited announced its unaudited financial results for the second quarter and half year ended September 2026. The company reported a consolidated revenue of ₹2,145 million (₹214.5 crore) for Q2 FY27, marking a 16% year-on-year increase from ₹1,845 million (₹184.5 crore) in Q2 FY26. Consolidated EBITDA grew by 20% to ₹721 million (₹72.1 crore) from ₹601 million (₹60.1 crore) in the prior year's quarter. Profit After Tax (PAT) rose by 14% to ₹512 million (₹51.2 crore) compared to ₹447 million (₹44.7 crore) in Q2 FY26. Earnings Per Share (EPS) stood at ₹4.33, up from ₹3.87 year-on-year.
On a quarter-on-quarter basis, revenue increased by 12% to ₹2,145 million (₹214.5 crore) from ₹1,917 million (₹191.7 crore) in Q1 FY27. EBITDA saw a significant jump of 36% to ₹721 million (₹72.1 crore) from ₹529 million (₹52.9 crore) in the previous quarter, and PAT grew by 33% to ₹512 million (₹51.2 crore) from ₹386 million (₹38.6 crore).
The company's operational performance showed growth across segments. Human Nutrition revenue increased by 6% year-on-year to ₹1,285 million (₹128.5 crore). Animal Nutrition grew by 37% to ₹265 million (₹26.5 crore), and Bio-Processing saw a strong 43% increase to ₹365 million (₹36.5 crore). Specialized Manufacturing revenue grew by 25% to ₹231 million (₹23.1 crore).
Geographically, domestic sales grew by 25% to ₹1,110 million (₹111 crore), constituting 52% of total revenue. International sales increased by 8% to ₹1,035 million (₹103.5 crore), representing 48% of revenue. The company also provided an outlook for FY27, focusing on expanding its product portfolio, particularly in probiotics, and replicating its B2C model in India with the launch of its nutraceutical brand, Wellfa. Advanced Enzymes also plans to expand its sales and marketing teams globally and explore strategic acquisition opportunities.
What to do with a filing like this
Advanced Enzyme Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Advanced Enzyme Technologies Limited. Read the original for the full detail.